Background
==========

Despite the popular use of vitamin supplements, the strong consumer belief is that they prevent chronic diseases such as cancer and cardiovascular disease (CVD) \[[@B1],[@B2]\], but results from randomized controlled trials are mixed \[[@B3]-[@B10]\]. Most randomized controlled trials show little support of a preventive effect of vitamin supplement use and even increased risk \[[@B6],[@B7]\] for cancer and CVD incidence and mortality, with some exceptions \[[@B8]-[@B10]\]. However, data from randomized controlled trials suffer from concerns about overreliance on secondary rather than primary prevention, insufficient intervention and follow-up periods, particularly regarding the incidence of cancer, inappropriate supplement doses, and unsuitable cohorts for testing the hypothesis. Therefore, studies for the effects of long-term, low doses of several agents in the general population are needed. Despite several prospective cohort studies investigating their effect on cancer incidence (all site \[[@B11],[@B12]\], colorectal \[[@B13]-[@B15]\], breast \[[@B16],[@B17]\], lung \[[@B18],[@B19]\], prostate \[[@B20]-[@B23]\], non-Hodgkin lymphoma \[[@B24]\]), and CVD incidence \[[@B11],[@B25]-[@B29]\], scientific data supporting their benefits remain controversial. Inconsistent results may be partly explained by the fact that use of supplements is an inconsistent behavior in individuals \[[@B13],[@B30]\]. Individuals with a favorable lifestyle and healthy diet are more likely to use vitamin supplementation consistently \[[@B30]\]. Some studies have found reduced risk for incidence and mortality of cancer and CVD associated with a long duration of vitamin supplement use \[[@B13],[@B14],[@B27],[@B28],[@B31]-[@B34]\]; however, consistent use of vitamin supplements could not be clearly determined by using a single time-point survey at baseline.

It is also important to note that the use of vitamin supplements is often associated with healthy lifestyle factors or with specific health issues, such as hypertension and cancer, that may increase or decrease vitamin supplement use \[[@B35],[@B36]\]. In Japan, a few cross-sectional studies reported that the prevalence of vitamin supplement use was approximately 10% to 30% of the study population and that vitamin supplement use was associated with several factors broadly characterized by health consciousness and conversely by poor health \[[@B37]-[@B39]\]. However, all prospective studies have been conducted in Western populations (United States \[[@B11]-[@B15],[@B17]-[@B29],[@B31]-[@B34]\] and European countries \[[@B16],[@B19],[@B25]\]). No data have been reported for prospective cohort studies in Asian general populations, although there are some randomized clinical trials \[[@B8],[@B40]\].

Therefore, we examined the association between vitamin supplement use and the risk of cancer and CVD in a population-based prospective cohort study in Japan. Participants in this cohort reported vitamin supplement use at two time points, which enabled us to examine the impact of the pattern of use on the risk of cancer and CVD.

Methods
=======

The Japan Public Health Center (JPHC)-Based Prospective Study was started in 1990 for cohort I and in 1993-1994 for cohort II. All subjects were Japanese inhabitants registered at 11 public health center areas and were aged 40-69 years at the time of their first survey. Details of the study design have been described previously \[[@B41]\]. In the present study, the subjects from two public health center areas (Katsushika in Tokyo prefecture and Suita in Osaka prefecture) were excluded because the incidence data for cancer or CVD were not available and the selection of subjects differed from that in other public health center areas. Of 116,896 people in nine public health areas, 95,405 (82%) individuals responded to the first survey. We excluded 1168 persons who were not Japanese, who had died or moved out of a study area, or who were lost to follow-up before the starting point. This left 94,237 eligible subjects. In 1995 and 1998, the second survey was conducted; 79,809 subjects replied (85%; 36,783 men and 43,026 women) and were included in the present study. The institutional review board of the National Cancer Center, Tokyo, Japan, approved the study.

The status of vitamin supplement use was defined by the responses in the two surveys and was classified into the following four categories of use: (1) never, no vitamin supplement use in either the first or second survey; (2) past, vitamin supplement use only in the first survey; (3) recent, vitamin supplement use only in the second survey; and (4) consistent, vitamin supplement use in both surveys. In the first survey, cohort I and cohort II subjects were asked how frequently they used vitamin supplements. Those who reported use on \>1 day/week were asked about the type of vitamin supplements. Use of vitamin supplements in the first survey was defined as subjects who used them at least 1 day/week. No information was collected on brand name or duration of vitamin supplement use. In the second survey for cohorts I and II, general use of any vitamin supplements more than once a week and use of specific vitamin supplements were examined. The brand names of vitamin supplements used were requested, and 81.7% provided this information. We used re-categorized self-reported categories of vitamin supplements based on the definition in the Women\'s Healthy Eating and Living Study \[[@B42]\] to improve sensitivity in identifying supplement use \[[@B43]\]. Details of the assessment of self-reported vitamin supplement use have been described previously, and use of vitamin supplements in the second survey was defined as subjects who used at least one type of vitamin supplement ≥ 1 week for ≥ 1 year \[[@B37],[@B43]\].

We followed subjects from the second survey until December 31, 2006, for cancer and until December 31, 2005, for CVD. We identified changes in residence status and survival annually through the residential registry in each area or, for those who had moved out of the area, by using the municipal office of the area to which they had moved. Residency registration and death registration are required by the Basic Residential Register Law and Family Registry Law, respectively, and the registries are thought to be complete. During the follow-up period, 8060 subjects (10.1%) died, 2106 (2.6%) moved out of the study areas, and 249 persons (0.31%) were lost to follow-up between the second survey and December 31, 2006.

The occurrence of cancer was identified by active patients\' notification from major local hospitals in the study area, that is, the extraction of clinical information from medical records into cohort-specific registration forms in either local major hospitals, which care for most of the patients with cancer or CVD (up to 80%) in some areas, by physicians in the hospital or physicians in the public health center \[[@B44]\], and from data linkage with population-based cancer registries, with permission from each of the local governments responsible for the cancer registries. Cases of cancer were coded according to the *International Classification of Disease for Oncology*, third edition, of the World Health Organization \[[@B45]\]. In our cancer registry system, the proportion of cases for which information was available from death certificates only was 4.4%. For the present analysis, the earliest date of diagnosis was used in cases with multiple cancer diagnoses at different times. Diagnosis of myocardial infarction according to the criteria of the Monitoring Trends and Determinants of Cardiovascular Disease (MONICA) project \[[@B46]\] and diagnosis of stroke according to the criteria of the National Survey of Stroke \[[@B47]\] were confirmed for all cases by computer tomographic scan, magnetic resonance imaging, or both as recorded in the medical record and reviewed by hospital or public health center physicians in each registered major local hospital in each public health center area \[[@B48],[@B49]\]. CVD cases with a death certificate or by self-report only, without confirmation by medical records, were treated as non-CVD cases. CVD was defined as myocardial infarction or stroke, whichever occurred first. Among the 79,809 subjects, we confirmed 5932 cases of newly diagnosed cancer by December 31, 2006, and 3218 cases of CVD by December 31, 2005. Participants with both cancer and CVD were included in both analyses.

From the 79,809 respondents, we excluded subjects with a history of cancer or CVD (*n*= 5809) and those who did not have information on their vitamin supplement use in both surveys (*n*= 11,371). Subjects with a history of cancer or CVD were defined as diagnosed with cancer or CVD before the starting point or from self-reports in the surveys. For the final analysis, 62,629 subjects (28,903 men and 33,726 women) remained, including 4501 with cancer and 1858 with CVD. We calculated person-years of follow-up for each subject from the starting point to the date of diagnosis, date of emigration from the study area, date of death, or end of the follow-up (December 31, 2006 for the cancer analysis and December 31, 2005 for the CVD analysis), whichever came first. We censored subjects lost to follow-up at the last confirmed date they were present in the study area. A total of 597,281 person-years were accrued for the cancer analysis and 547,983 for the CVD analysis. Sex-specific hazard ratios (HRs) and 95% confidence intervals (95% CIs) were used to describe the relative risks of total cancer and CVD associated with use of vitamin supplements. The Cox proportional hazards model was used to control for potential confounding factors, which were either known or suspected from previous studies as risk factors for cancer and CVD. All covariates were based on information from the second survey. We conducted the initial analyses by adjusting for age at the starting point (5-year groups) and study area (nine public health center areas). In the multivariate model, we further adjusted for smoking status (never, former, \<20, 20-29, 30-39, and ≥ 40 pack-years for men, and never, former, \<20, and ≥ 20 pack-years for women), alcohol consumption (none, \<150, 150-299, 300-449, and ≥ 450 g ethanol/week for men, and none, \<150, and ≥ 150 g ethanol/week for women), body mass index (\[BMI\] \<19, 19-20.9, 21-22.9, 23-24.9, 25-26.9, 27-29.9, and ≥ 30 kg/m^2^), occupation (farming, forestry, and fishing; employee and professional; housewife; self-employed; unemployed; other occupations; and combination \[≥ 2 occupations across those groups\]), quartile of physical activity in metabolic equivalent task-hours/day, total energy intake, energy-adjusted green vegetable intake, current medication status (hypertension, hyperlipidemia, or diabetes mellitus), and screening examination (blood pressure measurement, biochemical examination, electrocardiogram, fundus examination, chest radiograph, sputum cytology, gastric photofluorography, gastrointestinal endoscopy, fecal occult blood test, barium enema, or colonoscopy for men and women, and mammography or Papanicolaou smear for women), which were reported in a questionnaire in the second survey. As for current medication status and screening examination, if a subject replied \"yes\" to at least one medication or examination, we regarded the subject as using medication or taking the examination, respectively. The second survey included a food-frequency questionnaire consisting of 138 food items with standard portions/units and nine frequency categories, which were developed to estimate dietary intake \[[@B50]\] and validated for estimations of various nutrients and food groups \[[@B51]-[@B54]\]. A residual model was used for energy adjustment of green vegetable consumption, vitamin B~2~, vitamin B~6~, vitamin B~12~, folate, α-tocopherol, vitamin C, and vitamin D intake reported in food-frequency questionnaire \[[@B55]\]. Extreme values of BMI (\<14 or ≥ 40 kg/m^2^) and total energy intake (lower and upper 2.5 percentiles) were treated as missing values. Statistical significance was assumed at *P*\< 0.05. All statistical analyses were performed using SAS software, version 9.1 (SAS Institute, Cary, NC, USA).

Results
=======

Of the participants included in this analysis, 49,060 subjects (78.3%) reported no vitamin supplement use, 7833 subjects (12.5%) reported only past vitamin supplement use (in the first survey), 2593 subjects (4.2%) reported only recent vitamin supplement use (in the second survey), and 3143 subjects (5.0%) reported past and recent vitamin supplement use. Among subjects who used vitamin supplements and reported the brand name in the second survey, the most common vitamin supplement was B vitamins for men and women (multivitamin: 474 subjects \[25.8%\] and 566 subjects \[19.6%\]; antioxidants: 30 subjects \[1.6%\] and 126 subjects \[4.4%\]; vitamin A: 65 subjects \[3.5%\] and 144 subjects \[5.0%\]; B vitamins: 797 subjects \[43.5%\] and 883 subjects \[30.6%\]; vitamin C: 299 subjects \[16.3%\] and 656 subjects \[22.7%\]; vitamin E: 295 subjects \[16.1%\] and 843 subjects \[29.2%\]; other vitamins: 219 subjects \[11.9%\] and 443 subjects \[15.3%\], respectively).

Table [1](#T1){ref-type="table"} shows the baseline characteristics of the study subjects according to vitamin supplement use pattern in men and women separately. Individuals with past use and consistent use of vitamin supplements were significantly older for both sexes. Men who had never used supplements were thought to have lower health consciousness due to higher proportions with a BMI ≥ 25 kg/m^2^, a greater likelihood of being a smoker or regular drinker, less information on their disease history (angina, diabetes, colonic polyp, and hepatitis), fewer screening examinations, and less consumption of soy foods and fruits compared with other men. Significantly higher proportions of men with consistent supplement use took more medications (hyperlipidemia and diabetes), were more likely to have disease histories (angina, diabetes, duodenal ulcer, colonic polyp, and hepatitis), and may have higher health consciousness suggested by lower BMI, less regular drinking, more screening examinations, and higher consumption of fruits. Men with past supplement use also had a significantly higher proportion of antihypertensive medication use. Men with recent use also tended to have a healthy lifestyle and significantly lower proportions were smokers or taking diabetic medication. Women who had never used supplements were likely to have a healthier lifestyle, with significantly lower proportions being smokers or regular drinkers than other women. Women with recent or consistent use were also basically health conscious, having a lower BMI and a higher proportion of screening examinations, despite there being a significantly higher proportion of regular drinkers. Individuals with consistent use also consumed significantly larger amounts of fruits, folate, and vitamin C. They also tended to have significantly higher proportions of medication use (hypertension and hyperlipidemia) and history of diseases such as gastric and colonic polyps than those who never used supplements. Women with recent use were also more likely to have a history of gastric and colonic polyps, despite their younger age, and had a significantly higher proportion of medication use except for hypertension, hyperlipidemia, and diabetes. Women with past use tended to have an unhealthy lifestyle, including a higher BMI and a greater likelihood of smoking and medication use (hypertension and diabetes).

###### 

Population characteristics according to supplement use categories, Japan Public Health Center-based Prospective Study

                                                                         **Men (*n*= 28,903**)   Women (*n*= 33,726)                                                                                                           
  -------------------------------------------- ------------------------- ----------------------- --------------------- ------------- ------------- --------------- -------------- -------------- -------------- -------------- ---------
  No. (%)                                      23,535 (81.4)             3161 (10.9)             1026 (3.6)            1181 (4.1)                  25,525 (75.7)   4672 (13.9)    1567 (4.6)     1962 (5.8)                    
  Age in years (mean (SE\*))                   55.7 (0.05)               57.9 (0.1)              57.1 (0.2)            58.2 (0.2)    \<.0001       56.1 (0.05)     57.9 (0.1)     56.7 (0.2)     57.8 (0.2)     \<.0001        
  Body mass index ≥ 25 kg/m^2^(%)              29.1                      26.9                    27.1                  25.9          0.0049        29.0            31.0           26.3           23.6           \<.0001        
  Smoking status (%)                           Former smoker             16.6                    18.6                  19.5          21.3          \<.0001         0.7            1.2            1.7            1.4            \<.0001
                                               Current smoker            47.8                    44.8                  41.4          42.2                          4.3            5.7            4.7            5.2            
  Regular drinker, ≥ 150 g ethanol/wk (%)      50.5                      46.1                    46.8                  45.5          \<.0001       2.4             2.6            3.1            3.6            0.002          
  Mean MET\*-hours/d                           (mean (SE))               33.1 (0.05)             32.9 (0.1)            33.3 (0.2)    32.7 (0.2)    0.06            32.2 (0.04)    31.9 (0.09)    32.3 (0.2)     32.0 (0.1)     0.003
  Medication (%)                               Hypertension              16.7                    21.9                  17.0          21.5          \<.0001         17.8           24.4           18.1           20.0           \<.0001
                                               Hyperlipidemia            3.0                     4.3                   3.9           4.9           \<.0001         6.0            7.8            7.5            9.3            \<.0001
                                               Diabetes                  3.2                     4.2                   2.8           4.5           0.001           2.0            2.8            2.2            1.5            0.0005
                                               Others                    12.2                    17.1                  15.4          15.1          \<.0001         10.9           13.1           16.3           15.9           \<.0001
  History (%)                                  Angina                    0.9                     1.3                   1.1           1.6           0.03            1.0            1.2            1.5            1.2            0.2
                                               Diabetes                  5.8                     6.6                   5.8           7.5           0.04            3.0            3.4            3.3            2.5            0.2
                                               Gastric ulcer             5.0                     5.4                   5.0           4.9           0.8             2.1            2.3            2.6            2.9            0.07
                                               Duodenal ulcer            2.5                     2.0                   1.9           3.5           0.02            1.2            1.2            1.4            1.3            0.9
                                               Gastric polyp             2.2                     2.3                   2.6           3.3           0.09            2.6            2.4            3.3            3.7            0.004
                                               Colonic polyp             4.1                     4.3                   4.9           5.8           0.03            1.8            1.7            2.0            3.3            \<.0001
                                               Hepatitis                 1.7                     1.9                   2.3           3.2           0.0004          0.7            0.9            1.2            1.2            0.005
  Screening examination (%)                    83.3                      84.0                    87.0                  88.0          \<.0001       86.0            86.3           88.8           89.9           \<.0001        
  Total energy intake (kcal/day) (mean (SE))   2206 (4.2)                2200 (12.1)             2222 (20.4)           2228 (18.1)   0.5           1886 (3.6)      1879 (8.6)     1938 (14.5)    1925 (12.9)    0.0001         
  Energy-adjusted                              Salt intake (g/d)         12.2 (0.03)             12.3 (0.07)           12.4 (0.1)    12.3 (0.1)    0.5             12.0 (0.08)    11.9 (0.05)    11.7 (0.09)    11.7 (0.08)    0.5
  food intake                                  Soy food (g/d)            86 (0.5)                93 (1.6)              89 (2.3)      89 (1.8)      0.0001          86 (0.5)       94 (1.2)       86 (1.6)       89 (1.6)       \<.0001
  (mean (SE))                                  Green vegetables (g/d)    38 (0.2)                38 (0.6)              41 (1.2)      40 (1.0)      0.01            48 (0.2)       47 (0.6)       50 (1.1)       49 (0.8)       0.055
                                               Fruits (g/d)              172 (1.0)               187 (2.9)             189 (4.8)     204 (4.7)     \<.0001         239 (1.1)      242 (2.5)      242 (4.0)      254 (3.9)      0.001
                                               Fish (g/d)                91 (0.4)                91 (1.0)              92 (1.8)      92 (1.5)      0.7             87 (0.3)       86 (0.7)       86 (1.2)       86 (1.0)       0.4
                                               Red meat (g/d)            52 (0.3)                51 (0.7)              53 (1.3)      51 (1.0)      0.5             46 (0.2)       48 (0.5)       45 (0.8)       46 (0.7)       0.0009
  Energy-adjusted                              α-tocopherol (mg/d)       6.6 (0.02)              6.8 (0.05)            7.1 (0.08)    7.1 (0.07)    \<.0001         7.3 (0.01)     7.5 (0.03)     7.5 (0.05)     7.6 (0.05)     \<.0001
  nutrition intake                             Vitamin B~1~(mg/d)        1.05 (0.003)            1.10 (0.008)          1.08 (0.01)   1.11 (0.01)   \<.0001         1.08 (0.002)   1.12 (0.006)   1.11 (0.009)   1.11 (0.008)   \<.0001
  (mean (SE))                                  Vitamin B~2~(mg/d)        1.41 (0.003)            1.45 (0.009)          1.50 (0.02)   1.52 (0.01)   \<.0001         1.43 (0.003)   1.46 (0.007)   1.51 (0.01)    1.54 (0.01)    \<.0001
                                               Niacin (mg/d)             20.1 (0.04)             20.1 (0.1)            20.6 (0.2)    20.4 (0.1)    0.002           18.1 (0.03)    18.1 (0.07)    18.2 (0.1)     18.3 (0.09)    0.08
                                               Vitamin B~6~(mg/d)        1.56 (0.002)            1.58 (0.006)          1.60 (0.01)   1.60 (0.01)   \<.0001         1.46 (0.002)   1.47 (0.004)   1.48 (0.008)   1.49 (0.007)   \<.0001
                                               Vitamin B~12~(μ g/d)      9.1 (0.03)              9.2 (0.09)            9.3 (0.1)     9.4 (0.1)     0.02            8.6 (0.03)     8.7 (0.06)     8.7 (0.1)      8.6 (0.09)     0.2
                                               Folate (μ g/d)            377 (0.9)               385 (2.7)             401 (4.9)     399 (4.1)     \<.0001         409 (0.9)      413 (2.2)      422 (3.8)      426 (3.1)      \<.0001
                                               Pantothenic acid (mg/d)   6.7 (0.01)              6.8 (0.03)            6.9 (0.05)    7.1 (0.05)    \<.0001         6.6 (0.008)    6.7 (0.02)     6.8 (0.03)     6.9 (0.03)     \<.0001
                                               Vitamin C (mg/d)          118 (0.4)               122 (1.2)             128 (2.2)     130 (1.9)     \<.0001         151 (0.5)      149 (1.1)      154 (1.7)      158 (1.6)      \<.0001
                                               Vitamin D (mg/d)          10.1 (0.04)             10.0 (0.1)            10.4 (0.2)    10.3 (0.2)    0.2             10.0 (0.04)    9.9 (0.09)     9.9 (0.1)      9.9 (0.1)      0.4

Never use, neither past nor recent use; Past use, past use but not recent use; Recent use, recent use but not past use; Consistent use, both past and recent use.

\*SE, standard error; MET, metabolic equivalent task.

Associations of vitamin supplement use pattern and total cancer and CVD risk in men and women are shown separately in Table [2](#T2){ref-type="table"}. In men, no significant association was found between any pattern of vitamin supplement use and the risk of total cancer and CVD in age- and study area-adjusted and multivariate-adjusted models. No significant association was found between any specific vitamin supplement use in the second survey and total cancer and CVD. For women, however, a statistically significant increase in the risk of total cancer occurrence was observed in those with past and recent vitamin supplement use compared with those who never used supplements; the HR of developing cancer (95% CI) for past use and recent use was 1.17 (1.02-1.33) and 1.24 (1.01-1.52), respectively. When we performed separate analyses for major site-specific cancers, the HR of recent use in women was especially high for stomach cancer (HR 2.15, 95% CI 1.39-3.34). We also observed a nonsignificant but moderately increased risk of liver and pancreatic cancer with past supplement use in women (liver cancer: HR 1.61, 95% CI 0.95-2.74; pancreatic cancer: HR 1.67, 95% CI 0.94-2.97). When we estimated the HR after excluding women diagnosed as having cancer within 5 years of baseline, similar trends were observed, although the association for cancer with recent use was not significant and with past use remained significant. In the second survey, vitamin C supplements specifically and antioxidant supplementation, including two or more of β-carotene, vitamin C, vitamin E, and selenium \[[@B42]\], were significantly associated with an increased risk of total cancer; compared with the subjects with no vitamin supplement use, the HR and 95% CI of vitamin C supplement and antioxidant supplement use were 1.38 (1.03-1.87) and 1.83 (1.01-3.31), respectively. In contrast, we observed a statistically significant reduced risk for CVD with consistent vitamin supplement use for women (HR 0.60, 95% CI 0.41-0.89). When we performed separate analyses for coronary heart disease, hemorrhagic stroke, or ischemic brain infarction, decreased risk was observed for ischemic brain infarction with statistical significance with consistent use (coronary heart disease: HR 0.19, 95% CI 0.03-1.34; hemorrhagic stroke: HR 0.61, 95% CI 0.29-1.31; ischemic brain infarction: HR 0.52, 95% CI 0.28-0.98). HR estimates after excluding women diagnosed with CVD within 5 years of baseline showed a similar trend to estimates using all cases, although they were not statistically significant.

###### 

Hazard ratios for total cancer and cardiovascular disease according to supplement use categories

                                     Total                      Excluding cases within 5 years                                                              
  ------- ---------------- --------- -------------------------- -------------------------------- ------ ------------------ ------ ------ ------------------ ------
  Men                                                                                                                                                       
                                     *Total cancer*                                                                                                         
          Never use        220,948   2152                       1.00 (reference)                        1.00 (reference)          1210   1.00 (reference)   
          Past use         28,863    324                        0.98 (0.87-1.10)                 0.8    0.98 (0.87-1.10)   0.8    167    0.95 (0.80-1.11)   0.5
          Recent use       9603      102                        1.00 (0.82-1.22)                 0.97   1.01 (0.83-1.23)   0.9    59     1.05 (0.80-1.36)   0.7
          Consistent use   10,863    139                        1.11 (0.94-1.32)                 0.2    1.10 (0.93-1.31)   0.3    75     1.13 (0.89-1.43)   0.3
                                     *Cardiovascular disease*                                                                                               
          Never use        203,013   934                        1.00 (reference)                        1.00 (reference)          490    1.00 (reference)   
          Past use         26,639    125                        0.91 (0.75-1.09)                 0.3    0.89 (0.73-1.07)   0.2    61     0.86 (0.66-1.12)   0.3
          Recent use       8889      31                         0.71 (0.50-1.02)                 0.06   0.72 (0.51-1.04)   0.08   15     0.66 (0.39-1.10)   0.1
          Consistent use   10,059    53                         1.03 (0.78-1.36)                 0.8    1.02 (0.77-1.35)   0.9    28     1.04 (0.71-1.53)   0.8
                                                                                                                                                            
  Women                                                                                                                                                     
                                     *Total cancer*                                                                                                         
          Never use        248,659   1299                       1.00 (reference)                        1.00 (reference)          698    1.00 (reference)   
          Past use         44,237    287                        1.19 (1.04-1.35)                 0.01   1.17 (1.02-1.33)   0.02   157    1.21 (1.01-1.44)   0.04
          Recent use       15,217    101                        1.25 (1.02-1.53)                 0.03   1.24 (1.01-1.52)   0.04   56     1.26 (0.96-1.66)   0.1
          Consistent use   18,892    97                         0.94 (0.76-1.16)                 0.6    0.92 (0.75-1.13)   0.4    47     0.82 (0.61-1.11)   0.2
                                     *Cardiovascular disease*                                                                                               
          Never use        227,570   530                        1.00 (reference)                        1.00 (reference)          262    1.00 (reference)   
          Past use         40,586    116                        1.11 (0.91-1.36)                 0.3    1.08 (0.88-1.32)   0.5    63     1.24 (0.94-1.64)   0.1
          Recent use       13,918    43                         1.30 (0.95-1.77)                 0.1    1.32 (0.97-1.81)   0.08   20     1.26 (0.80-1.99)   0.3
          Consistent use   17,309    26                         0.60 (0.40-0.89)                 0.01   0.60 (0.41-0.89)   0.01   14     0.70 (0.41-1.21)   0.2

Never use, neither past nor recent use; Past use, past use but not recent use; Recent use, recent use but not past use; Consistent use, both past and recent use.

\*HR, hazard ratio; CI, confidence interval.

HR1: Adjusted for age and public health center area.

HR2: Further adjusted for body mass index, smoking status, ethanol intake, occupation, daily total physical activity level, green vegetable intake, total energy intake, medication, and screening examination.

These statistically significant findings remained unchanged when we further adjusted dietary vitamin B~2~, B~6~, B~12~, folate, α-tocopherol, vitamin C, and vitamin D intake separately and simultaneously (data not shown).

Age, smoking status, alcohol intake, and dietary intake of vitamin B~2~, B~6~, B~12~, folate, α-tocopherol, vitamin C, and vitamin D did not significantly interact with any of the above results (for all interactions, *P*\> 0.5).

Discussion
==========

In this prospective cohort study in an Asian population, we found that vitamin supplement use has little effect on the risk of total cancer or CVD in men. In women, however, past and recent use of vitamin supplements may be associated with higher risk of cancer, whereas consistent use may be associated with lower risk of CVD.

Several observational studies have examined the association between vitamin supplements and the risk of cancer and CVD incidence, but results have varied \[[@B11]-[@B29]\], partly because vitamin supplement use is an inconsistent behavior in individuals \[[@B13],[@B30]\]. In our study, we found that only 4.1% of men and 5.8% of women continued to use vitamin supplements from the first to the second survey. Although some studies have found reduced incidence and mortality risk of cancer and CVD with a long duration of vitamin supplement use \[[@B13],[@B14],[@B27],[@B28],[@B31]-[@B34]\], to our knowledge, only limited data are available to clarify the consistency of vitamin supplement use over two surveys \[[@B13],[@B31]\]. One prospective cohort study in the United States investigated consistency for vitamin supplement use through two surveys among 145,260 subjects, observing 797 incident cases of colorectal cancer, and found that multivitamin supplement use in the first survey and in both surveys was associated with reduced risk of colorectal cancer, whereas multivitamin supplement use in the second survey had no association with the disease \[[@B13]\]. Another study, in which 3490 deaths were observed among 11,178 study subjects in the United States, found that use of vitamin E supplements at two points within a relatively short period (baseline and study inception 3 years earlier) was associated with reduced risk of coronary heart disease mortality, whereas use at one point did not show significant association in multivariate analysis \[[@B31]\].

In the present study, the inverse associations for CVD, especially for ischemic brain infarction, was observed with consistent supplement use in women. It is known that homocysteine may promote atherogenesis by damaging the vascular matrix, increasing the proliferation of endothelial cells, and facilitating oxidative injury to vascular walls \[[@B56]-[@B58]\] and may be related to CVD \[[@B59],[@B60]\]. Although several large trials of homocysteine-lowering B-vitamin therapy have all failed to demonstrate a reduction in coronary heart disease risk, some studies have shown possible evidence for stroke \[[@B9],[@B10]\]. It has also been reported that B vitamins are important enzymatic cofactors in the synthesis of methionine from homocysteine and that a deficiency in any of them raises homocysteine concentrations in the blood \[[@B61],[@B62]\]. In the present study, when we adjusted for several kinds of dietary B vitamins (vitamin B~2~, vitamin B~6~, vitamin B~12~, and folate), similar results were observed. Moreover, the most common vitamin supplement in the second survey was B vitamins in men and women in the present study (36.1% and 25.0%, respectively, among vitamin supplement users). Therefore, the inverse association between the consistent use of vitamin supplement and risk of CVD in women, especially ischemic brain infarction, might be caused by supplementation with B vitamins.

Alternatively, past and recent use of vitamin supplements was associated with higher risk of cancer in women. Women with past use tended to have unhealthy characteristics, such as a higher BMI, a greater likelihood of smoking, and medication use (hypertension and diabetes). Recent use in women may have been prompted by symptoms of ill health because women with recent use had a higher proportion of disease histories (e.g., gastric and colonic polyps) despite their younger age and had a significantly higher proportion of medication use except for hypertension, hyperlipidemia, and diabetes. Furthermore, the association of cancer with recent use was not significant when we estimated the HR after excluding women diagnosed as having cancer within 5 years of baseline, though that might be partly caused by the decreased number of cases. Elevated risk may be partly explained by characteristics of the women that were not measured or could not be controlled for in our study. Moreover, it might be partly caused by a pro-oxidant effect of supplementation with vitamin C \[[@B63]-[@B65]\], producing DNA damage and increasing the risk of cancer, because use of vitamin C in the second survey was associated with increased risk of total cancer among women. Furthermore, high-dose antioxidant supplementation might cause an increased risk of cancer among a high-risk group; in addition, two large, randomized clinical trials in which high doses of β-carotene were used, the Beta-Carotene And Retinol Efficacy Trial (CARET) in the United States and the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) trial in Finland, found that β-carotene, alone or in combination with vitamin E or retinyl palmitate, increased the incidence of lung cancers compared with placebo among high-risk groups, such as heavy smokers and those with a history of exposure to asbestos \[[@B6],[@B7]\].

In the present study, vitamin supplement use was associated with the risk of total cancer or CVD in women but not in men. The characteristics of subjects with each vitamin supplement pattern were different between men and women, suggesting that these characteristics and unmeasured or residual confounders might cause the sex-based difference in results.

Our study has a potential limitation due to the differences in questionnaires regarding vitamin supplement use between the first and second surveys, and these differences might cause misclassification of vitamin supplement use prevalence, which was lower in the second survey than that in the first survey. Short-time vitamin supplement use of \<1 year was regarded as vitamin supplement use in the first survey. In the second survey, re-categorized self-reported categories of vitamin supplementation were used to improve sensitivity in identifying vitamin supplement use \[[@B43]\] and vitamin supplement use was defined by vitamin supplements being taken ≥ 1 time/week for a year or longer. Information of duration was not available in the first survey. In addition, the possibility of selection bias needs to be considered when generalizing the present findings because 15% of the eligible subjects did not reply in the second survey. In our previous report, risks of mortality for all causes, all cancers, and CVD were higher among non-responders to the first survey compared with responders and elevated risk for cancer was observed only in the first 2 years of follow-up, whereas that for stroke was relatively stable for the entire period \[[@B66]\].

The strength of this study was its prospective design, which enabled us to avoid exposure recall bias. We selected subjects from the general population, we kept the sample size large, the response rate for the surveys was acceptable given its setting, and the loss to follow-up was negligible. In addition, the registries of cancer, stroke, and myocardial infarction were of sufficient quality to reduce the misclassification of outcomes. To our knowledge, this is the first prospective cohort study to examine associations between vitamin supplement use pattern and risk of cancer and CVD incidence simultaneously.

Conclusions
===========

Allowing for the methodologic issues, our results from a population-based prospective cohort study in Japan suggest that vitamin supplement use pattern has an impact on the subsequent risk of total cancer and CVD in women but not men. Elevated risk of cancer among women who were past and recent users of vitamin supplements may be partly explained by preexisting diseases or unhealthy background, which could not be completely controlled for in our study. Although consistent use of vitamin supplements for women might possibly reduce the risk of CVD, further research with detailed long-term data regarding components, doses, and patterns of vitamin supplement use is needed to confirm the generalizability of our findings.
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